Zeitschrift für Hämatologie und thromboembolische Erkrankungen
Offener Zugang

Abstrakt

Cancer and Thrombosis

Zahra Mozaheb

Venous thromboembolism (VTE) is a common and life-threatening condition in patients with cancer. The incidence rate depends on the tumor type. Many of risk factors for development of VTE are common in patients with cancer, which include cancer related factors and treatment related factors. In this review we define VTA to include deep vein thrombosis (DVT), pulmonary embolism (PE), superficial vein thrombisis (SVT), Splanchnic vein thromboses (SPVT), Involving the splenic, portal, mesenteric, or hepatic veins. Prophylactic anticoagulation therapy recommended for patients with active cancer who do not have a contraindication are Low molecular Wight heparins, fondaparinox, and subcutaneous Unfractionated Heparin, warfarin, and aspirin only for low risk multiple myeloma. In cancer patients low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy with a vitamin K antagonist.